The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results. 

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 
By Claire Marie Porter
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account